Researchers at the University of Houston (UH) are recommending a new strategy for developing drugs to treat cancer, multiple sclerosis, Alzheimer's and cardiovascular diseases.
In an invited review published in the October issue of Nature Reviews Drug Discovery, scientists at the Center for Nuclear Receptors and Cell Signaling (CNRCS) at UH outline the results of years of research following the team's 1996 discovery of the estrogen receptor beta (ERβ).
"We have known for some time that female sex hormones -- estrogens -- influence a number of functions in the human body," said Dr. Jan-Åke Gustafsson, UH professor and CNRCS director. "Only recently have we and others found that one of the estrogen receptors -- ERβ -- is a potential target for the treatment of Alzheimer's and other chronic diseases."
Gustafsson is best known as a leading expert on estrogen receptors, being credited with the earlier discovery of ERβ during his tenure at the Karolinska Institutet in Stockholm, Sweden. In Houston since 2009, Gustafsson has hand-selected a team of experts to build on his initial breakthrough. For this latest review, the team was invited to share the most recent results of their research.
The two estrogen receptors, estrogen receptor alpha (ERα) and ERβ, have their effects on cells via activation by hormones circulating in the body. The influence of these receptors in the human body spans such diverse functions as fertility, metabolism, and the cardiovascular and nervous systems. Due to their expanded role in human health, these receptors represent an ideal target for drugs and therapeutic treatments.
Studies conducted following Gustafsson's discovery of ERβ have shown intriguing differences in tissue distribution and gene regulation when compared to the role of ERα. There has since been an intense effort in both academia and industry to develop ERβ-specific research tools and potential therapeutics for a multitude of conditions.
One successful example of using ERβ as a drug target has proven the receptor as an effective cancer cell combatant in breast cancer tissue. Closer examination of human breast cancer cell lines determined that, while ERα alone may stimulate the development of tumors, the combined presence of ERα and ERβ reduced and prevented tumor development.
"These modulators are well-established in the treatment of breast cancer and osteoporosis," Gustafsson said. "We now are pushing the limits of their influence to develop new treatments and ultimately save lives."
CNRCS researchers continue to examine the two estrogen receptor subtypes in various animal disease models, focused on identifying therapeutic opportunities. ERβ remains the most likely target for expanding treatments beyond breast cancer. The widespread involvement of ERβ presents the greatest probability for impacting these other diseases. Early results indicate that the selective activation of ERβ may represent a safe, disease-modifying therapy for the treatment of Alzheimer's disease.
Collaborators included Konrad F. Koehler and Stefan Nilsson of Karo Bio, a pharmaceutical company in Sweden. Gustafsson's research is funded by the Texas Emerging Technology Fund, the Robert A. Welch Foundation and the Cancer Prevention and Research Institute of Texas.
- Stefan Nilsson, Konrad F. Koehler, Jan-Åke Gustafsson. Development of subtype-selective oestrogen receptor-based therapeutics. Nature Reviews Drug Discovery, 2011; 10 (10): 778 DOI: 10.1038/nrd3551
Cite This Page: